melanoma, Merkel cell carcinoma (MCC), Metastatic/advanced soft tissue sarcoma (STS), triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).
Conditions
Brief summary
Phase I part: Overall incidence of AEs and DLTs, SAEs, Phase IIa part - Soft Tissue Sarcoma cohort: Progression Free Rate at 6-months according to iRECIST, Phase IIa part - All cohorts except Soft Tissue Sarcoma : Immune Overall Response Rate according to iRECIST.
Detailed description
Overall incidence of AEs and DLTs, SAEs (Phase IIa part), Disease Control rate overall and at 4-month using RECIST 1.1 and iRECIST, Progression Free Survival using RECIST 1.1 and iRECIST, Overall Survival
Interventions
Sponsors
Transgene
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase I part: Overall incidence of AEs and DLTs, SAEs, Phase IIa part - Soft Tissue Sarcoma cohort: Progression Free Rate at 6-months according to iRECIST, Phase IIa part - All cohorts except Soft Tissue Sarcoma : Immune Overall Response Rate according to iRECIST. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall incidence of AEs and DLTs, SAEs (Phase IIa part), Disease Control rate overall and at 4-month using RECIST 1.1 and iRECIST, Progression Free Survival using RECIST 1.1 and iRECIST, Overall Survival | — |
Countries
Belgium, France
Outcome results
None listed